Formerly senior vice president and head of early development at Vigil Neuroscience, Evan is now serving as an EIR at Atlas Venture. While at Vigil, he built both the nonclinical and CMC organizations and brought multiple TREM2 agonist molecules into the clinic. Vigil was acquired by Sanofi in 2025. Previously, Evan was head of nonclinical development at Ra Pharmaceuticals. There, he worked on the C5 peptide inhibitor Zilucoplan prior to Ra’s acquisition by UCB. Before joining Ra, Evan held positions of increasing responsibility over 7 years at Genentech. He focused his work primarily on ophthalmology (Lucentis, Susvimo) and oncology (Avastin, Polivy) indications, as well as cross-functional program leadership. He also led the efforts to develop long-acting intravitreal delivery systems for Roche/Genentech. Evan began his career as a program toxicologist at the Schering Plough Research Institute, and holds a Ph.D. in Environmental and Molecular Toxicology from the University of Wisconsin.